Growth Metrics

Pfizer (PFE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $102.0 billion.

  • Pfizer's Total Non-Current Liabilities fell 836.92% to $102.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $102.0 billion, marking a year-over-year decrease of 836.92%. This contributed to the annual value of $6.2 billion for FY2024, which is 345.12% up from last year.
  • Latest data reveals that Pfizer reported Total Non-Current Liabilities of $102.0 billion as of Q3 2025, which was down 836.92% from $103.2 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Total Non-Current Liabilities registered a high of $113.4 billion during Q1 2024, and its lowest value of $5.2 billion during Q4 2021.
  • Its 5-year average for Total Non-Current Liabilities is $70.4 billion, with a median of $89.6 billion in 2022.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 1330.3% in 2021, then surged by 50148.08% in 2023.
  • Pfizer's Total Non-Current Liabilities (Quarter) stood at $6.5 billion in 2021, then decreased by 8.26% to $6.0 billion in 2022, then grew by 0.03% to $6.0 billion in 2023, then increased by 3.45% to $6.2 billion in 2024, then surged by 1544.32% to $102.0 billion in 2025.
  • Its Total Non-Current Liabilities stands at $102.0 billion for Q3 2025, versus $103.2 billion for Q2 2025 and $104.1 billion for Q1 2025.